- Healthcare 150
- Posts
- FDA Shifts Rare Disease Rules as Biotech M&A Heats Up
FDA Shifts Rare Disease Rules as Biotech M&A Heats Up
Rare Disease Biotech Could Get a New Risk Profile
Gaston Brizuela Bosio
October 15, 2026
Good morning, ! Today we’re covering the FDA’s new Rare Disease Framework, Galderma’s $1.5 billion acquisition of ZO Skin Health, and the technologies reshaping Europe’s biotech landscape, led by AI, mRNA, and next-generation drug discovery tools.
Want to advertise in Healthcare 150? Check out our ad platform, here.
Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.
— The Healthcare150 Team
MICROSURVEY
Which healthcare segment do you expect to see the strongest M&A activity over the next 12 months? |
HEADLINE OF THE WEEK
Rare Disease Biotech Could Get a New Risk Profile
The FDA’s new Rare Disease Framework Initiative could materially change the economics of orphan drug development. With only 5% of rare diseases currently having an FDA approved treatment, the agency is exploring more flexible clinical evidence requirements, tailored regulatory reviews, and risk based manufacturing oversight.
That matters because rare disease programs often face an uncomfortable combination of small patient populations, expensive trials, complex manufacturing, and uncertain regulatory pathways. Reducing those frictions could make programs that previously failed investment screens economically viable.
The second order effect may be on capital allocation. Smaller biotechs could pursue narrower indications with less development burden, while larger pharma companies gain a deeper pool of de risked licensing and acquisition targets.
Why it matters: If the FDA converts flexibility into predictable regulatory pathways, rare disease biotech could shift from a high science, high regulatory risk category toward a more investable pipeline model. The key uncertainty is execution. Frameworks attract capital only when approval precedent follows. (More)
DEAL OF THE WEEK
Galderma’s $1.5B Bet on Physician Dispensed Skincare
Galderma is acquiring ZO Skin Health for $1.5 billion, its largest transaction since going public in 2024. ZO generated roughly $330 million in sales over the 12 months through June, implying an enterprise value of about 4.5x revenue.
The strategic fit is distribution as much as product. ZO is particularly strong in med spas, while Galderma’s Alastin franchise has greater exposure to dermatologists and plastic surgeons. Combining the two expands Galderma’s reach across the physician dispensed skincare channel, a category management says is growing 5% to 8% annually.
Why it matters: Galderma is effectively buying deeper control of the increasingly valuable intersection between medical aesthetics and premium skincare. The deal also signals that clinically positioned skincare brands with practitioner distribution can command strategic premiums as aesthetics companies push beyond procedures into recurring consumer spend.
The acquisition is expected to be core EPS neutral in its first full year after closing, limiting near term earnings upside while Galderma works to accelerate ZO’s growth. (More)
DEAL TRACKER
BlackRock (HPS) → CenterWell Senior Primary Care JV, from WCAS | ~$2.8B (WCAS stake)
HPS, part of BlackRock, will buy Welsh Carson's equity in Humana's network of about 150 CenterWell senior primary-care clinics and take majority control of a new JV. It's expected to close in Q4 2026. Read more
STERIS → Xodus Medical | $2.1B at close + up to $150M earnout
STERIS is adding Xodus's consumable surgical-safety line (Pink Pad), which is expected to bring in about $245M of revenue in 2026. Closing is targeted by Dec 31, 2026, subject to regulatory approval. Read more
Roche → Rona Therapeutics ALK7 RNAi | up to ~$1.16B ($100M upfront/near-term + $1.06B milestones)
Roche took an exclusive worldwide license to an extrahepatic RNAi obesity asset that aims to cut fat while sparing lean mass. Read more
Agilent → Proscia | $240M cash + up to $30M milestones
Agilent gets an enterprise digital pathology software platform used by 4,000+ labs and 16 of the top 20 pharma companies. Read more
L Catterton + Altas Partners → Fullscript (majority), from HGGC & Snapdragon | Undisclosed
This is a sponsor-to-sponsor deal for a whole-person-care platform that serves practitioners. It's expected to close in Q4. Read more
REGIONAL FOCUS
Europe’s Biotech Stack Is Moving Upstream
Europe’s biotech outlook is increasingly being shaped by technologies that improve how drugs are discovered, designed, and validated. AI enabled life science data mining ranks first, cited by 85%, followed by mRNA vaccines at 82% and omics technologies at 78%. Tissue engineering (77%) and CRISPR Cas (76%) are close behind.
The narrow spread matters. Europe is not converging around a single breakthrough technology. Instead, the data points to a broader technology stack spanning computational discovery, molecular data, advanced therapeutics, and gene editing.
For investors and operators, that raises the value of platforms that can connect these capabilities rather than compete within one modality. AI may sit at the top of the ranking, but its strategic value will depend on access to high quality biological data and its ability to translate that data into development decisions. (More)
